Does the media favor AMLX or PTCT?

In the previous week, PTC Therapeutics had 12 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for PTC Therapeutics and 1 mentions for Amylyx Pharmaceuticals. PTC Therapeutics' average media sentiment score of 0.49 beat Amylyx Pharmaceuticals' score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AMLX or CNTA more profitable?

Amylyx Pharmaceuticals' return on equity of -55.69% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -55.69% -50.73% Centessa Pharmaceuticals N/A -60.37% -44.17%

Does the media favor AMLX or CNTA?

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 3 mentions for Centessa Pharmaceuticals and 1 mentions for Amylyx Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Centessa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or AMLX?

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 1 mentions for Amylyx Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RYTM or AMLX?

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 1 mentions for Amylyx Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AMLX or COGT more profitable?

Amylyx Pharmaceuticals' return on equity of -55.69% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -55.69% -50.73% Cogent Biosciences N/A -104.27% -54.64%

Does the media favor AMLX or COGT?

In the previous week, Cogent Biosciences had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Amylyx Pharmaceuticals. Cogent Biosciences' average media sentiment score of 0.54 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Amylyx Pharmaceuticals (AMLX) Competitors

$16.37 +0.09 (+0.55%)

As of 04:00 PM Eastern

Compare

AMLX vs. PTCT, CNTA, MIRM, RYTM, and COGT

Should you buy Amylyx Pharmaceuticals stock or one of its competitors? MarketBeat compares Amylyx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amylyx Pharmaceuticals include PTC Therapeutics (PTCT), Centessa Pharmaceuticals (CNTA), Mirum Pharmaceuticals (MIRM), Rhythm Pharmaceuticals (RYTM), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does Amylyx Pharmaceuticals compare to PTC Therapeutics?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

PTC Therapeutics has higher revenue and earnings than Amylyx Pharmaceuticals. PTC Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	20.88	-$144.74M	-$1.50	N/A
PTC Therapeutics	$1.73B	3.94	$682.64M	-$2.33	N/A

Amylyx Pharmaceuticals has a beta of -0.16, meaning that its share price is 116% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Amylyx Pharmaceuticals presently has a consensus price target of $23.00, indicating a potential upside of 40.16%. PTC Therapeutics has a consensus price target of $91.36, indicating a potential upside of 11.23%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Amylyx Pharmaceuticals is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, PTC Therapeutics had 12 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for PTC Therapeutics and 1 mentions for Amylyx Pharmaceuticals. PTC Therapeutics' average media sentiment score of 0.49 beat Amylyx Pharmaceuticals' score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PTC Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Amylyx Pharmaceuticals' return on equity of -55.69% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Summary

Amylyx Pharmaceuticals beats PTC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Centessa Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Amylyx Pharmaceuticals has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	20.88	-$144.74M	-$1.50	N/A
Centessa Pharmaceuticals	$15M	417.48	-$197.53M	-$1.79	N/A

Amylyx Pharmaceuticals' return on equity of -55.69% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Amylyx Pharmaceuticals currently has a consensus target price of $23.00, suggesting a potential upside of 40.16%. Centessa Pharmaceuticals has a consensus target price of $41.33, suggesting a potential upside of 2.08%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Amylyx Pharmaceuticals is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Amylyx Pharmaceuticals has a beta of -0.16, suggesting that its share price is 116% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 3 mentions for Centessa Pharmaceuticals and 1 mentions for Amylyx Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Centessa Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amylyx Pharmaceuticals beats Centessa Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 1 mentions for Amylyx Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.16, suggesting that its stock price is 116% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.85	-$23.36M	-$13.61	N/A
Amylyx Pharmaceuticals	$87.37M	20.88	-$144.74M	-$1.50	N/A

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Mirum Pharmaceuticals currently has a consensus target price of $139.80, suggesting a potential upside of 27.28%. Amylyx Pharmaceuticals has a consensus target price of $23.00, suggesting a potential upside of 40.16%. Given Amylyx Pharmaceuticals' higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Mirum Pharmaceuticals beats Amylyx Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Rhythm Pharmaceuticals currently has a consensus price target of $133.13, suggesting a potential upside of 25.21%. Amylyx Pharmaceuticals has a consensus price target of $23.00, suggesting a potential upside of 40.16%. Given Amylyx Pharmaceuticals' higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 1 mentions for Amylyx Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Rhythm Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.16, meaning that its stock price is 116% less volatile than the broader market.

Amylyx Pharmaceuticals has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$217.17M	33.55	-$196.54M	-$3.13	N/A
Amylyx Pharmaceuticals	$87.37M	20.88	-$144.74M	-$1.50	N/A

Summary

Rhythm Pharmaceuticals and Amylyx Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Cogent Biosciences?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Cogent Biosciences had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Amylyx Pharmaceuticals. Cogent Biosciences' average media sentiment score of 0.54 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has a beta of -0.16, meaning that its stock price is 116% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Amylyx Pharmaceuticals has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	20.88	-$144.74M	-$1.50	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Amylyx Pharmaceuticals currently has a consensus target price of $23.00, suggesting a potential upside of 40.16%. Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 20.13%. Given Amylyx Pharmaceuticals' higher possible upside, research analysts clearly believe Amylyx Pharmaceuticals is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Amylyx Pharmaceuticals' return on equity of -55.69% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Cogent Biosciences	N/A	-104.27%	-54.64%

Summary

Amylyx Pharmaceuticals beats Cogent Biosciences on 9 of the 15 factors compared between the two stocks.

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMLX vs. The Competition

Export

Metric	Amylyx Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.82B	$2.98B	$6.48B	$12.13B
Dividend Yield	N/A	1.78%	2.68%	5.81%
P/E Ratio	-10.94	18.38	24.66	24.01
Price / Sales	20.88	341.78	529.89	110.00
Price / Cash	N/A	55.91	27.92	37.84
Price / Book	5.90	4.12	10.84	6.53
Net Income	-$144.74M	$64.45M	$3.56B	$336.99M
7 Day Performance	9.04%	2.58%	1.71%	-0.18%
1 Month Performance	20.84%	1.31%	0.48%	0.83%
1 Year Performance	226.89%	30.87%	32.98%	31.55%

Amylyx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMLX Amylyx Pharmaceuticals	2.0209 of 5 stars	$16.37 +0.6%	$23.00 +40.5%	+222.4%	$1.82B	$87.37M	N/A	200	News Coverage
PTCT PTC Therapeutics	2.4474 of 5 stars	$76.77 +2.2%	$91.36 +19.0%	+61.3%	$6.23B	$1.73B	N/A	1,410	News Coverage Insider Trade High Trading Volume
CNTA Centessa Pharmaceuticals	1.5879 of 5 stars	$39.76 +0.1%	$41.33 +4.0%	+223.3%	$6.14B	$15M	N/A	200
MIRM Mirum Pharmaceuticals	3.9901 of 5 stars	$101.00 +1.7%	$139.80 +38.4%	+114.1%	$6.06B	$521.31M	N/A	140	Gap Down
RYTM Rhythm Pharmaceuticals	2.8992 of 5 stars	$89.70 +1.5%	$132.63 +47.9%	+63.6%	$6.06B	$189.76M	N/A	140	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMLX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. PTCT, CNTA, MIRM, RYTM, and COGT

How does Amylyx Pharmaceuticals compare to PTC Therapeutics?

Summary

How does Amylyx Pharmaceuticals compare to Centessa Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. PTCT, CNTA, MIRM, RYTM, and COGT

How does Amylyx Pharmaceuticals compare to PTC Therapeutics?

Which has preferable valuation & earnings, AMLX or PTCT?

Which has more volatility & risk, AMLX or PTCT?

Do analysts recommend AMLX or PTCT?

Does the media favor AMLX or PTCT?

Do insiders & institutionals believe in AMLX or PTCT?

Is AMLX or PTCT more profitable?

Summary

How does Amylyx Pharmaceuticals compare to Centessa Pharmaceuticals?

Which has higher valuation and earnings, AMLX or CNTA?

Is AMLX or CNTA more profitable?

Do analysts recommend AMLX or CNTA?

Do institutionals & insiders have more ownership in AMLX or CNTA?

Which has more volatility and risk, AMLX or CNTA?

Does the media favor AMLX or CNTA?

Summary

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Does the media prefer MIRM or AMLX?

Which has more risk and volatility, MIRM or AMLX?

Which has preferable valuation and earnings, MIRM or AMLX?

Is MIRM or AMLX more profitable?

Do analysts recommend MIRM or AMLX?

Do institutionals and insiders have more ownership in MIRM or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Is RYTM or AMLX more profitable?

Do analysts rate RYTM or AMLX?

Does the media prefer RYTM or AMLX?

Do institutionals and insiders hold more shares of RYTM or AMLX?

Which has more volatility and risk, RYTM or AMLX?

Which has stronger valuation & earnings, RYTM or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Cogent Biosciences?

Does the media favor AMLX or COGT?

Which has more volatility & risk, AMLX or COGT?

Do institutionals and insiders have more ownership in AMLX or COGT?

Which has stronger earnings & valuation, AMLX or COGT?

Do analysts prefer AMLX or COGT?

Is AMLX or COGT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools